Cargando…
A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
BACKGROUND: Cuproptosis, a form of copper-dependent programmed cell death recently presented by Tsvetkov et al., have been identified as a potential therapeutic target for refractory cancers and ferroptosis, a well-known form describing iron-dependent cell death. However, whether the crossing of cup...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465684/ https://www.ncbi.nlm.nih.gov/pubmed/37405477 http://dx.doi.org/10.1007/s00432-023-05005-5 |
_version_ | 1785098726910459904 |
---|---|
author | Li, Jianan Liu, Jixuan Li, Jixian Feng, Alei Nie, Yuanliu Yang, Zhe Zhang, Wentao |
author_facet | Li, Jianan Liu, Jixuan Li, Jixian Feng, Alei Nie, Yuanliu Yang, Zhe Zhang, Wentao |
author_sort | Li, Jianan |
collection | PubMed |
description | BACKGROUND: Cuproptosis, a form of copper-dependent programmed cell death recently presented by Tsvetkov et al., have been identified as a potential therapeutic target for refractory cancers and ferroptosis, a well-known form describing iron-dependent cell death. However, whether the crossing of cuproptosis-related genes and ferroptosis-related genes can introduce some new idea, thus being used as a novel clinical and therapeutic predictor in esophageal squamous cell carcinoma (ESCC) remains unknown. METHODS: We collected ESCC patient data from the Gene Expression Omnibus and the Cancer Genome Atlas databases and used Gene Set Variation Analysis to score each sample based on cuproptosis and ferroptosis. We then performed weighted gene co-expression network analysis to identify cuproptosis and ferroptosis-related genes (CFRGs) and construct a ferroptosis and cuproptosis-related risk prognostic model, which we validated using a test group. We also investigated the relationship between the risk score and other molecular features, such as signaling pathways, immune infiltration, and mutation status. RESULTS: Four CFRGs (MIDN, C15orf65, COMTD1 and RAP2B) were identified to construct our risk prognostic model. Patients were classified into low- and high-risk groups based on our risk prognostic model and the low-risk group showed significantly higher survival possibilities (P < 0.001). We used the “GO”, “cibersort” and “ESTIMATE” methods to the above-mentioned genes to estimate the relationship among the risk score, correlated pathways, immune infiltration, and tumor purity. CONCLUSION: We constructed a prognostic model using four CFRGs and demonstrated its potential clinical and therapeutic guidance value for ESCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-05005-5. |
format | Online Article Text |
id | pubmed-10465684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-104656842023-08-31 A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis Li, Jianan Liu, Jixuan Li, Jixian Feng, Alei Nie, Yuanliu Yang, Zhe Zhang, Wentao J Cancer Res Clin Oncol Research BACKGROUND: Cuproptosis, a form of copper-dependent programmed cell death recently presented by Tsvetkov et al., have been identified as a potential therapeutic target for refractory cancers and ferroptosis, a well-known form describing iron-dependent cell death. However, whether the crossing of cuproptosis-related genes and ferroptosis-related genes can introduce some new idea, thus being used as a novel clinical and therapeutic predictor in esophageal squamous cell carcinoma (ESCC) remains unknown. METHODS: We collected ESCC patient data from the Gene Expression Omnibus and the Cancer Genome Atlas databases and used Gene Set Variation Analysis to score each sample based on cuproptosis and ferroptosis. We then performed weighted gene co-expression network analysis to identify cuproptosis and ferroptosis-related genes (CFRGs) and construct a ferroptosis and cuproptosis-related risk prognostic model, which we validated using a test group. We also investigated the relationship between the risk score and other molecular features, such as signaling pathways, immune infiltration, and mutation status. RESULTS: Four CFRGs (MIDN, C15orf65, COMTD1 and RAP2B) were identified to construct our risk prognostic model. Patients were classified into low- and high-risk groups based on our risk prognostic model and the low-risk group showed significantly higher survival possibilities (P < 0.001). We used the “GO”, “cibersort” and “ESTIMATE” methods to the above-mentioned genes to estimate the relationship among the risk score, correlated pathways, immune infiltration, and tumor purity. CONCLUSION: We constructed a prognostic model using four CFRGs and demonstrated its potential clinical and therapeutic guidance value for ESCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-05005-5. Springer Berlin Heidelberg 2023-07-05 2023 /pmc/articles/PMC10465684/ /pubmed/37405477 http://dx.doi.org/10.1007/s00432-023-05005-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Li, Jianan Liu, Jixuan Li, Jixian Feng, Alei Nie, Yuanliu Yang, Zhe Zhang, Wentao A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis |
title | A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis |
title_full | A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis |
title_fullStr | A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis |
title_full_unstemmed | A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis |
title_short | A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis |
title_sort | risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465684/ https://www.ncbi.nlm.nih.gov/pubmed/37405477 http://dx.doi.org/10.1007/s00432-023-05005-5 |
work_keys_str_mv | AT lijianan ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT liujixuan ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT lijixian ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT fengalei ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT nieyuanliu ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT yangzhe ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT zhangwentao ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT lijianan riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT liujixuan riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT lijixian riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT fengalei riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT nieyuanliu riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT yangzhe riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis AT zhangwentao riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis |